OPRX OptimizeRx Corp

Nasdaq optimizerx.com


$ 19.82 $ -0.61 (-2.99 %)    

Thursday, 16-Oct-2025 15:59:56 EDT
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 19.78
$ 20.50
$ 19.45 x 13
$ 21.00 x 260
$ 19.66 - $ 20.85
$ 3.78 - $ 20.85
272,140
na
376.13M
$ 1.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-15-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 04-15-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-10-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-08-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-02-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-01-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-08-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-23

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

Core News & Articles

Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OO...

 optimizerx-appoints-brendan-merrell-as-coo

OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life scie...

 jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-20

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

 stifel-maintains-buy-on-optimizerx-raises-price-target-to-18

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $16 to $18.

 optimizerx-stock-rallies-22-after-hours-thanks-to-q2-earnings-push

OptimizeRx's stock jumped 22.66% after hours following strong Q2 earnings that beat expectations and lifted the share price...

 optimizerx-raises-fy2025-sales-guidance-from-101000m-106000m-to-104000m-108000m-vs-103365m-est

2025 Financial OutlookThe Company is increasing its 2025 guidance and expects revenue to be between $104 million and $108 milli...

 optimizerx-q2-adj-eps-024-beats-002-estimate-sales-29195m-beat-22264m-estimate

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.02 by 1...

 optimizerx-and-simulmedia-join-forces-to-enable-real-time-data-driven-tv-advertising-for-life-sciences-with-privacy-forward-audience-targeting

Strategic Collaboration Brings Precision Micro-Neighborhood Targeting Healthcare Consumer Audiences to Linear and Connected TV

 stifel-maintains-buy-on-optimizerx-raises-price-target-to-16

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $12.5 to $16.

 stifel-maintains-buy-on-optimizerx-raises-price-target-to-125

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $8 to $12.5.

 jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-14

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION